OppenheimerFunds Inc. boosted its position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 5.8% during the second quarter, HoldingsChannel.com reports. The fund owned 319,850 shares of the company’s stock after acquiring an additional 17,415 shares during the quarter. OppenheimerFunds Inc.’s holdings in Aerie Pharmaceuticals were worth $21,605,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AERI. American Century Companies Inc. raised its stake in Aerie Pharmaceuticals by 67.7% during the 1st quarter. American Century Companies Inc. now owns 56,339 shares of the company’s stock worth $3,056,000 after acquiring an additional 22,751 shares during the period. Prudential Financial Inc. raised its stake in Aerie Pharmaceuticals by 9.2% during the 1st quarter. Prudential Financial Inc. now owns 57,910 shares of the company’s stock worth $3,142,000 after acquiring an additional 4,890 shares during the period. Swiss National Bank raised its stake in Aerie Pharmaceuticals by 2.5% during the 1st quarter. Swiss National Bank now owns 53,900 shares of the company’s stock worth $2,924,000 after acquiring an additional 1,300 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Aerie Pharmaceuticals by 10.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 182,345 shares of the company’s stock worth $9,893,000 after acquiring an additional 17,740 shares during the period. Finally, Thrivent Financial for Lutherans raised its stake in Aerie Pharmaceuticals by 1.3% during the 1st quarter. Thrivent Financial for Lutherans now owns 108,311 shares of the company’s stock worth $5,876,000 after acquiring an additional 1,411 shares during the period. Institutional investors own 96.00% of the company’s stock.

In other news, COO Thomas A. Mitro sold 190,000 shares of Aerie Pharmaceuticals stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $60.27, for a total transaction of $11,451,300.00. Following the sale, the chief operating officer now owns 234,147 shares in the company, valued at $14,112,039.69. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Casey C. Kopczynski sold 11,000 shares of Aerie Pharmaceuticals stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $68.30, for a total transaction of $751,300.00. Following the sale, the insider now owns 163,307 shares in the company, valued at approximately $11,153,868.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 257,512 shares of company stock worth $15,670,247. Company insiders own 10.53% of the company’s stock.

Aerie Pharmaceuticals stock opened at $59.15 on Monday. The company has a market cap of $2.64 billion, a PE ratio of -17.55 and a beta of 0.77. The company has a current ratio of 10.27, a quick ratio of 10.07 and a debt-to-equity ratio of 0.64. Aerie Pharmaceuticals Inc has a 1 year low of $47.05 and a 1 year high of $74.75.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.16). The firm had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $1.16 million. analysts anticipate that Aerie Pharmaceuticals Inc will post -4.51 earnings per share for the current fiscal year.

AERI has been the topic of a number of recent analyst reports. ValuEngine cut shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 26th. BidaskClub cut shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, September 1st. Mizuho restated a “buy” rating and set a $77.00 target price on shares of Aerie Pharmaceuticals in a research note on Friday, June 1st. Canaccord Genuity set a $86.00 price objective on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, June 5th. Finally, Cowen lifted their price objective on shares of Aerie Pharmaceuticals from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $83.10.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Story: Google Finance

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.